Thomas Schinecker, Roche CEO (ddp images/Sipa USA/Sipa via AP Images)
Roche cuts two more TIGIT trials, plans accelerated timeline for obesity drugs
A year into Roche’s comprehensive portfolio review, the Swiss pharma said it has now taken out 25% of new drug candidates from its pipeline. The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
